Chartwell Rx Ll Patent-Cliff Exposure & CMS Drug Spending Portfolio

Chartwell Rx Ll (US): 6 reconciled FDA prescription therapies, $960K 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$960K
2024 Medicare Part D Spend$179K
2024 Medicaid Spend$781K
California HCAI SB 17 Filings5 WAC filings (max 132.4% 2-yr change)